Innocan Pharma closes private placement

1 GERMAN minute read
31 Dezember 2020
Client work

Team:

Jason Saltzman, Joseph McDonald, J. Quinn Clement-Schlimm

On December 31, 2020, Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) closed a non-brokered private placement offering of units for aggregate gross proceeds of $2,367,804.

Innocan is an Israeli pharmaceutical technology company that focuses on the development of several drug delivery platforms combining cannabidiol ("CBD") with other pharmaceutical ingredients.

Gowling WLG advised Innocan with respect to this private placement with a team that included Jason A. Saltzman, Joseph McDonald and Quinn Clement-Schlimm.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Cannabis, Corporate Commercial, Capital Markets

Team

Related Insights & Resources

View all insights Related Insights & Resources
Client work
17 Mai 2022 Innocan Pharma obtains receipt for final base shelf prospectus
Client work
13 Mai 2022 Unified Global completes merger with Fiore Cannabis
Client work
12 Mai 2022 Plant-Based Investment Corp. acquires CGOC Management Corp., its management company

Team

Download or print PDF